Syed Rubina Zaidi

Dr. Syed Rubina Zaidi

Clinical Trails Unit, Department of Hematology, University of Eastern Piedmont Amedeo Avogadro, Novara, Piedmont, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AMAbdurraouf Mokhtar Mahmoud
Abdurraouf Mokhtar Mahmoud
JTJasmitaben Prakashbhai Touti
Jasmitaben Prakashbhai Touti
SZSyed Rubina Zaidi
Syed Rubina Zaidi
AKAhad Ahmed Kodipad
Ahad Ahmed Kodipad
CDClara Deambrogi
Clara Deambrogi
The integration of emerging technologies and real-world data is transforming the landscape of hematologic clinical trials. Artificial intelligence (AI) offers remarkable capabilities for predictive modeling, patient stratification, and adaptive trial design, while circulating tumor DNA (ctDNA) provides a minimally invasive biomarker for disease monitoring, the early detection of relapse, and treatment response assessment. Concurrently, real-world evidence (RWE) complements traditional clinical trial data by capturing treatment effectiveness, safety, and patient outcomes in broader, heterogeneous populations. This review examines the synergistic potential of AI, ctDNA, and RWE to optimize trial design and decision-making in hematologic malignancies. We discuss methodological innovations, including AI-driven patient selection, ctDNA-guided adaptive interventions, and the incorporation of RWE for external control arms and post-marketing surveillance. Key challenges, such as data standardization, regulatory considerations, and ethical implications, are also addressed. By integrating these advanced tools, clinical trials in hematology can achieve greater efficiency, precision, and translatability, ultimately accelerating the development of personalized therapies and improving patient outcomes.

26 December 2022 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SZSyed Rubina Zaidi
Syed Rubina Zaidi
ABAshutosh Badola
Ashutosh Badola
Alzheimer's disease (AD), a multifaceted neurological ailment that progresses over time, is the most common cause of dementia in older people. Intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contribute to senile plaques on a pathological level. AD symptoms vary depending on the stage of the disease. Depending on the severity of cognitive impairment, AD is classified as preclinical or presymptomatic, mild, or dementia-stage. In addition, the condition is influenced by a number of risk factors, including advancing age, hereditary factors, head injuries, vascular diseases, infections, and environmental variables. There are currently only two types of licenced medications to treat AD: inhibitors of the cholinesterase enzyme such as donepezil, rivastigmine, galantamine and antagonists of N-methyl d-aspartate (NMDA) such as memantine, both of which are only effective in treating the symptoms of the disease and do not cure or prevent it.